2019
DOI: 10.1080/00016489.2019.1592221
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of intratympanic corticosteroid, intravenous batroxobin and combined treatment for sudden sensorineural hearing loss with type-2 diabetes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
8
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(9 citation statements)
references
References 18 publications
1
8
0
Order By: Relevance
“…The result demonstrated that the comparison of the total effective rate and efficacy of the treatment of diabetes patients with SHL by posterior auricular and tympanum injection of dexamethasone showed no statistical differences. The outcome was consistent with the research result obtained by Jia et al (2019) [ 8 ]. The further analysis of pain and the incidence of adverse reactions among patients after the treatment by the two methods revealed that the VAS value in the retroauricular group decreased more remarkably than that in the tympanic group ( P < 0.01), and pain VAS score was obviously lower than that in tympanic group ( P < 0.001).…”
Section: Discussionsupporting
confidence: 93%
See 1 more Smart Citation
“…The result demonstrated that the comparison of the total effective rate and efficacy of the treatment of diabetes patients with SHL by posterior auricular and tympanum injection of dexamethasone showed no statistical differences. The outcome was consistent with the research result obtained by Jia et al (2019) [ 8 ]. The further analysis of pain and the incidence of adverse reactions among patients after the treatment by the two methods revealed that the VAS value in the retroauricular group decreased more remarkably than that in the tympanic group ( P < 0.01), and pain VAS score was obviously lower than that in tympanic group ( P < 0.001).…”
Section: Discussionsupporting
confidence: 93%
“…At the early stage of diabetes, minor damage to peripheral organs and dysfunction of the auditory center and peripheral nervous system may occur [ 7 ]. In some studies, it is pointed out that 16% of SHL patients suffer from combined diabetes [ 8 ]. The treatment of SHL patients with diabetes by glucocorticoid causes an increase in glyconeogenesis, the reduction in peripheral glucose utilization, and the aggravation of diabetes [ 9 ].…”
Section: Introductionmentioning
confidence: 99%
“…After assessing the remaining 99 full-text articles, 41 studies were excluded for the following reasons: foreign language (n = 3), case reports (n = 3), review or meta-analysis (n = 10), and no mention of complications (n = 25). Finally, 58 studies 1-5,9-61 were included in the systemic review and meta-analysis including 25 randomized controlled trials, 10 prospective studies, and 22 retrospective case-controlled studies ( Table 1 ). A total of 2824 patients served as participants in the meta-analysis wherein 2567 received ITSI via TC (54 articles) and 257 received ITSI via VT (4 articles).…”
Section: Resultsmentioning
confidence: 99%
“…Reports have suggested to withhold batroxobin use if the brinogen is lowered below 80 mg/dL. For brinogen above 400 mg/dL, a batroxobin dose of 20 units per 250 mL saline has been used 50 . De brinogenation using batroxobin in addition to steroid therapy improved hearing as per the case report published by Narita et.…”
Section: Discussionmentioning
confidence: 99%